Biodesix announces two presentations on lung cancer treatment guidance tests at the iaslc 2023 world lung conference on lung cancer

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that two abstracts will be presented at the international association for the study of lung cancer (iaslc) 2023 world lung conference on lung cancer (wclc). the first presentation showcases a new analysis of the large multi-center observational registry study insight (clinical effectiveness assessment of veristrat® testing and validatio.
BDSX Ratings Summary
BDSX Quant Ranking